Novartis Sees Signifor Cleared by FDA, Teva’s JV in Korea: Healthcare Business Recap

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Signifor, made by Novartis (NYSE:NVS), was cleared by the FDA to treat the rare hormone condition known as Cushing’s disease. The approval was for patients who can’t be helped with surgery. Signifor reduces excess levels of the hormone cortisol caused by a tumor on the pituitary gland at the base of the brain.

The FDA approves GlaxoSmithKline’s (NYSE:GSK) Fluarix Quadrivalent influenza virus vaccine for the immunization of children three years of age and up and adults to help prevent disease caused by seasonal influenza virus subtypes A and type B which are  contained in the vaccine. The medicine marks the first intramuscular vaccine to cover against four influenza strains.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Shares of Vivus (NASDAQ:VVUS) were up almost 15 percent in afternoon trading Monday after analysts at Bloomberg Industries said that Qsymia prescriptions has soared by 46% week-over-week, according to data from Symphony Health Solutions.

Teva Pharmaceutical Industries (NYSE:TEVA) of Israel enters into a joint venture with South Korea’s Handok Pharmaceuticals with gaining a foothold in the $14 billion Korean market in mind. The final deal ends months of chatter that Teva was interested in making an purchase in Korea in which the Israeli company noted that healthcare spending should reach as much as 9 percent of gross domestic product by 2015.

Don’t Miss: Wall Street to Washington: It’s Time to Lead, or Leave!


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business